Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)

10/19/2020 | 09:16am EST
Item 8.01 Other Events.



On October 19, 2020, AbbVie Inc. issued a press release announcing the commencement of its offers to exchange any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior unsecured notes previously issued on November 21, 2019, (ii) $13,251,781,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020 and (iii) €2,517,066,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020, each issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), for an equal principal amount of new notes in a transaction registered under the Securities Act. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein in its entirety.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
  No.        Exhibit

  99.1         Press Release dated October 19, 2020.
104          The cover page from this Current Report on Form 8-K formatted in Inline
             XBRL (included as Exhibit 101).




                                       2

© Edgar Online, source Glimpses

All news about ABBVIE INC.
08:41aABBVIE : Working With Frontier Medicines to Develop Therapeutics
DJ
08:02aABBVIE : and Frontier Medicines Establish Global Partnership to Discover and Dev..
PR
08:01aFRONTIER MEDICINES : and AbbVie Establish Global Partnership to Discover and Dev..
PR
12/01ABBVIE : to Host Virtual Immunology Strategic Update
PR
11/25ABBVIE : to Present at the Evercore ISI Conference and Piper Sandler Healthcare ..
AQ
11/24ABBVIE : to Present at the Evercore ISI Conference and Piper Sandler Healthcare ..
PR
11/19ABBVIE : Announces Expiration and Final Results of Registered Exchange Offers
AQ
11/18ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/18ABBVIE : Announces Expiration and Final Results of Registered Exchange Offers
PR
11/18Berkshire's bet a bright spot in gloomy year for Big Pharma stocks
RE
More news
Financials (USD)
Sales 2020 45 620 M - -
Net income 2020 12 365 M - -
Net Debt 2020 74 496 M - -
P/E ratio 2020 25,4x
Yield 2020 4,54%
Capitalization 184 B 184 B -
EV / Sales 2020 5,66x
EV / Sales 2021 4,59x
Nbr of Employees 47 000
Free-Float 98,5%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 111,64 $
Last Close Price 104,04 $
Spread / Highest target 22,1%
Spread / Average Target 7,30%
Spread / Lowest Target -6,77%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.17.51%183 680
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415